SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla secures USFDA’s approval for AIDS treatment drug nevirapine

03 May 2012 Evaluate

Cipla, one of the world’s leading generic pharmaceutical companies in collaboration with Drugs for Neglected Diseases Initiative (DNDi) has received US Food and Drug Administration’s (USFDA) approval for acquired immune deficiency syndrome (AIDS) treatment drug nevirapine. The drug is a generic version of German drug-maker Boehringer Ingelheim's Viramune tablets.

Recently, the company had announced that it is planning to launch the Fixed-Dose combination of ‘Artesunate (AS) 1 + Mefloquine (MQ) 2’ for the treatment of uncomplicated P. falciparum malaria. The combination of AS and MQ is proven to be a safe, rapid and reliably effective treatment for uncomplicated P. falciparum malaria and is recommended by the World Health Organization (WHO).

Cipla Share Price

1228.15 -10.15 (-0.82%)
20-Apr-2026 15:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1666.00
Dr. Reddys Lab 1229.50
Cipla 1228.15
Zydus Lifesciences 934.00
Lupin 2329.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×